# Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

> **NCT01267188** · PHASE2 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 10 (estimated)

## Conditions studied

- Tardive Dyskinesia

## Interventions

- **DRUG:** NBI-98854

## Key facts

- **NCT ID:** NCT01267188
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2011-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01267188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01267188, "Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01267188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*